Myeloma News
Limited Efficacy Seen With Ixazomib Plus Daratumumab and Low-Dose Dexamethasone in Intermediate-Fit Patients With MM
Source: Myeloma – Hematology Advisor
Researchers sought to determine whether ixazomib plus daratumumab and low-dose dexamethasone would be effective in intermediate-fit patients with MM.
Read More
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies
New Vaccine Significantly Improved Lifespan of Patients With Multiple Myeloma in Phase 1 Trial
Source: Pharmacy Times articles
Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.
Read More
A dendritic cell vaccine was safe and induced immune responses in patients with multiple myeloma
A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk multiple myeloma.
Read More
Final Results of DREAMM-2 Show Durable Responses With Belantamab Mafodotin
Source: Myeloma – Hematology Advisor
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Read More
Higher Rate of Infections After AHCT for Multiple Myeloma Seen in India
Source: Myeloma – Hematology Advisor
Researchers sought to determine rates of infections for patients with multiple myeloma receiving autologous transplantation in India compared to other countries.
Read More
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Disentangling age, gender, and racial/ethnic disparities in multiple myeloma burden: a modeling study
Suboptimal Response to Induction Therapy May Predict Poor Survival After ASCT in Multiple Myeloma
Source: Myeloma – Hematology Advisor
Researchers sought to determine survival outcomes of ASCT in patients with multiple myeloma who had a suboptimal response to induction therapy.
Read More
Recent Publications
Real-life experience with plasmapheresis in newly diagnosed multiple myeloma accompanied by acute kidney injury
Ir J Med Sci. 2023 Sep 28. doi: 10.1007/s11845-023-03535-y. Online ahead of print. ABSTRACT OBJECTIVES: The aim of this study was to retrospectively evaluate the effect of plasmapheresis treatment concomitant with chemotherapy and the number of sessions on renal improvement and survival in...
A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma
Cancers (Basel). 2023 Sep 13;15(18):4533. doi: 10.3390/cancers15184533. ABSTRACT Multiple myeloma (MM) is an incurable malignancy of plasma cells and the second most common hematologic malignancy in the United States. Although antibodies in clinical cancer therapy are generally of the IgG class,...
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Cancers (Basel). 2023 Sep 21;15(18):4667. doi: 10.3390/cancers15184667. ABSTRACT Renal function impairment (RI) is a common complication in multiple myeloma (MM). However, limited data exist on the safety and efficacy of anti-MM regimens in patients with severe RI, as these patients are frequently...
Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma
Int J Mol Sci. 2023 Sep 14;24(18):14097. doi: 10.3390/ijms241814097. ABSTRACT Lenalidomide, a well-established drug for the treatment of multiple myeloma, significantly enhances patients' survival. Previous clinical studies have demonstrated that its main side effect is an increased risk of...
Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
Life (Basel). 2023 Aug 31;13(9):1841. doi: 10.3390/life13091841. ABSTRACT Anti-CD38 monoclonal antibody (MoAB) therapy has significantly improved the prognosis of patients with multiple myeloma. However, not all patients sustain durable responses. We aimed to describe the natural history of...
Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective
J Patient Exp. 2023 Sep 25;10:23743735231202733. doi: 10.1177/23743735231202733. eCollection 2023. ABSTRACT A qualitative study of the experiences of patients who received autologous stem cell transplant (ASCT) for the treatment of multiple myeloma (MM) was conducted to better understand their MM...
Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients
Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283831. Online ahead of print. ABSTRACT Not available. PMID:37767561 | DOI:10.3324/haematol.2023.283831
Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma
Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.282789. Online ahead of print. ABSTRACT Multiple myeloma (MM) remains incurable due to drug resistance. Ribosomal protein S3 (RPS3) has been identified as a non-Rel subunit of NF-κB. However, the detailed biological roles of RPS3 remain...
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
